Current Report Filing (8-k)
01 Août 2019 - 1:46PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 1, 2019
INTELLIA THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-37766
|
|
36-4785571
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
40 Erie Street, Suite 130
Cambridge, Massachusetts 02139
(Address of Principal Executive Offices, and Zip Code)
(857)
285-6200
Registrants Telephone Number, Including Area Code
Not Applicable
Former
name or former address, if changed since last report
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communication pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communication pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each Class
|
|
Trade
Symbol(s)
|
|
Name of Each Exchange
on Which Registered
|
Common Stock, par value $0.0001 per share
|
|
NTLA
|
|
The Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933(17 CFR §230.405) or Rule
12b-2
of the Securities Exchange Act of 1934 (17 CFR
§240.12b-2).
Emerging growth company ☐
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 2.02.
|
Results of Operations and Financial Condition.
|
On August 1, 2019, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended June 30, 2019. The full
text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 on this Current Report on Form
8-K.
The information in this report furnished pursuant to Item 2.02 shall not be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if
such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
EXHIBIT INDEX
|
|
|
Exhibit
Number
|
|
Description of Exhibit
|
|
|
99.1
|
|
Press release dated August 1, 2019
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this Report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Intellia Therapeutics, Inc.
|
|
|
|
|
Date: August 1, 2019
|
|
|
|
By:
|
|
/s/ John M. Leonard
|
|
|
|
|
Name:
|
|
John M. Leonard
|
|
|
|
|
Title:
|
|
Chief Executive Officer and President
|
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2024 à Août 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Août 2023 à Août 2024